Aggiornamento aziendale28 set 2026ENGENFIT Reports First-Half 2026 Financial Results and Provides Corporate UpdateGENFIT S.A.Company newsroom
Aggiornamento aziendale14 set 2026ENGENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLFGENFIT S.A.Company newsroom
Aggiornamento aziendale11 set 2026ENGENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext ParisGENFIT S.A.Company newsroom
Aggiornamento aziendale10 set 2026ENGENFIT to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGENFIT S.A.Company newsroom
Aggiornamento aziendale9 set 2026ENGENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics TechnologyGENFIT S.A.Company newsroom
Aggiornamento aziendale3 set 2026ENGENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026GENFIT S.A.Company newsroom
Aggiornamento aziendale8 lug 2026ENGenfit: Half-Year Report of Liquidity Contract with Crédit Industriel et CommercialGENFIT S.A.Company newsroom
Aggiornamento aziendale2 lug 2026ENGENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASHGENFIT S.A.Company newsroom
Aggiornamento aziendale23 giu 2026ENGENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with CholangiocarcinomaGENFIT S.A.Company newsroom
Aggiornamento aziendale15 giu 2026ENGENFIT: June 15, 2026 Combined Shareholders Meeting ResultsGENFIT S.A.Company newsroom
Aggiornamento aziendale8 giu 2026ENGENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASHGENFIT S.A.Company newsroom
Aggiornamento aziendale25 mag 2026ENGENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026GENFIT S.A.Company newsroom
Aggiornamento aziendale21 mag 2026ENGENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate UpdateGENFIT S.A.Company newsroom
Aggiornamento aziendale11 mag 2026ENGENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory DocumentsGENFIT S.A.Company newsroom
Aggiornamento aziendale20 apr 2026ENGENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)GENFIT S.A.Company newsroom
Aggiornamento aziendale7 apr 2026ENGENFIT Announces Publication of the 2025 Universal Registration DocumentGENFIT S.A.Company newsroom
Aggiornamento aziendale2 apr 2026ENGENFIT Reports Full-Year 2025 Financial Results and Provides Corporate UpdateGENFIT S.A.Company newsroom
Aggiornamento aziendale9 mar 2026ENGENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLFGENFIT S.A.Company newsroom
Aggiornamento aziendale26 feb 2026ENGENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate UpdateGENFIT S.A.Company newsroom
Aggiornamento aziendale12 feb 2026ENGENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net salesGENFIT S.A.Company newsroom
